Stock Notification: Sandomigran, pizotifen 0.5 mg (as maleate) tablet

Sandomigran, pizotifen 0.5 mg (as maleate) tablet AUST R 69608

In July 2015, AFT Pharmaceuticals Pty Ltd took over the sponsorship of Sandomigran tablets from Novartis Pharmaceuticals Pty Ltd.

AFT Pharmaceuticals Pty Ltd are currently out of stock of this product at their warehouse. This situation has arisen as a consequence of the change of sponsorship affecting production of the finished product.

It is our understanding that wholesalers are typically holding between 4 and 6 weeks stock of the product which we are hoping this stock holding will prevent unavailability of the product to patients.

We are arranging to take delivery of 15,000 units of stock which will expire in June 2016. This stock is expected to be available for distribution by late November 2015. In addition, AFT Pharmaceuticals have an application with the TGA which when approved will allow for a further 78,000 units to become available.

It is anticipated that normal production and subsequent supply of the product will re-commence from February 2016.

We thank you for your understanding of the situation.

November 20, 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…

Read More

November 12, 2025

AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market 

AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…

Read More

September 25, 2025

On track for $300m FY27 revenue; positive iron IV study result

– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …

Read More